Clinical Trial Update: A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia. [Phase 2]

View source ↗

Summary

A Phase 2 pilot study evaluating Pardoprunox as an add-on to L-dopa in advanced Parkinson's disease with motor fluctuations and dyskinesia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Pardoprunox (pardoprunox)

Snippet

Sponsor: Abbott Products | Conditions: Advanced Stage Parkinson's Disease | Phase 2 | Status: TERMINATED